Prasugrel

Expert Opin Investig Drugs. 2006 Dec;15(12):1627-33. doi: 10.1517/13543784.15.12.1627.

Abstract

Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyridine derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y(12) receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.

Publication types

  • Review

MeSH terms

  • Adenosine Diphosphate / antagonists & inhibitors
  • Adenosine Diphosphate / pharmacology
  • Animals
  • Aspirin / administration & dosage
  • Aspirin / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase III as Topic
  • Clopidogrel
  • Collagen / antagonists & inhibitors
  • Collagen / pharmacology
  • Coronary Disease / drug therapy
  • Drug Evaluation, Preclinical
  • Drug Resistance
  • Drug Synergism
  • Drug Therapy, Combination
  • Drugs, Investigational* / administration & dosage
  • Drugs, Investigational* / adverse effects
  • Drugs, Investigational* / pharmacokinetics
  • Drugs, Investigational* / pharmacology
  • Drugs, Investigational* / therapeutic use
  • Humans
  • Piperazines* / administration & dosage
  • Piperazines* / adverse effects
  • Piperazines* / pharmacokinetics
  • Piperazines* / pharmacology
  • Piperazines* / therapeutic use
  • Platelet Activation / drug effects
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors* / administration & dosage
  • Platelet Aggregation Inhibitors* / adverse effects
  • Platelet Aggregation Inhibitors* / pharmacokinetics
  • Platelet Aggregation Inhibitors* / pharmacology
  • Platelet Aggregation Inhibitors* / therapeutic use
  • Prasugrel Hydrochloride
  • Prodrugs / pharmacokinetics
  • Prodrugs / therapeutic use
  • Purinergic P2 Receptor Antagonists*
  • Pyridines / administration & dosage
  • Pyridines / therapeutic use
  • Rats
  • Receptors, Purinergic P2Y12
  • Thiophenes* / administration & dosage
  • Thiophenes* / adverse effects
  • Thiophenes* / pharmacokinetics
  • Thiophenes* / pharmacology
  • Thiophenes* / therapeutic use
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / chemistry
  • Ticlopidine / pharmacology
  • Ticlopidine / therapeutic use

Substances

  • Drugs, Investigational
  • P2RY12 protein, human
  • Piperazines
  • Platelet Aggregation Inhibitors
  • Prodrugs
  • Purinergic P2 Receptor Antagonists
  • Pyridines
  • Receptors, Purinergic P2Y12
  • Thiophenes
  • thienopyridine
  • Adenosine Diphosphate
  • Collagen
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine
  • Aspirin